Method
Level · gp.fundamentals.capex_revenue_ratio
Raw value 4.33% · OPTIONAL
· Pharmaceutical Preparations
RESEARCH SNAPSHOTTonix Pharmaceuticals Holding Corp.'s latest supported as-filed period reports revenue of $13.5M. Every value below links to its SEC accession and metric lineage.
No material rule-based research observation currently meets GrossPattern's Insight value threshold. Current state, direction, and filing evidence remain available below.
A multidimensional view of the latest comparable filing—not a composite score or recommendation.
Level · gp.fundamentals.capex_revenue_ratio
Raw value 4.33% · OPTIONAL
Ratio · gp.fundamentals.operating_cash_flow + gp.fundamentals.revenue
Raw value -311.89% · OPTIONAL
Yoy · gp.fundamentals.revenue
Raw value 577.88% · CORE
Level · gp.fundamentals.gross_margin
Raw value 94.81% · CORE
Level · gp.fundamentals.operating_margin
Raw value -314.05% · CORE
Ratio · gp.fundamentals.rnd + gp.fundamentals.revenue
Raw value 143.36% · OPTIONAL
Business direction, financial quality, capital allocation, and governance evidence remain separate—never collapsed into a recommendation score.
Interpretation boundary Direction describes measurable company fundamentals. Governance reports observable evidence only; it does not grade management character or predict stock returns.
Latest available comparable states within 180 days, normalized with robust median/MAD statistics.
The most important deterministic changes, ranked by magnitude, issuer history, persistence, and accounting profile.
This cluster groups 3 independently calculated changes: Revenue increased 577.9%; Operating margin moved 110217 bp higher; Operating income decreased 50.3%.
3 evidence-backed componentsThis cluster groups 3 independently calculated changes: Revenue increased 577.9%; Operating margin moved 110217 bp higher; Operating income decreased 50.3%.
3 evidence-backed componentsFree-cash-flow proxy changed -178.8% from the comparable as-filed period. The change ranks at the 100th percentile of 4 prior comparable changes.
Each point keeps the date investors could first observe it and its accession.
TNXP · as filed with the SEC · reported-date aware
Direct SEC links, filing dates, report periods, and amendment flags.
0001493152-26-041689SEC ↗4Aug 31, 2026Period Aug 27, 20260001493152-26-040736SEC ↗4Aug 24, 2026Period Aug 20, 20260001999371-26-018494SEC ↗8-KAug 18, 2026Period Aug 18, 20260001493152-26-039000SEC ↗10-QAug 10, 2026Period Jun 30, 20260001999371-26-017452SEC ↗8-KAug 10, 2026Period Aug 10, 20260001493152-26-036740SEC ↗8-KAug 3, 2026Period Aug 3, 20260001493152-26-035741SEC ↗8-KTransaction semantics distinguish purchases, sales, awards, exercises, withholding, and derivatives.
GrossPattern stores immutable raw artifacts, accession-scoped facts, parser and metric versions, dependency edges, quality state, and channel-specific publication rights. A restricted or unknown ancestor blocks the page and API automatically.
SEC source policy ↗Level · gp.fundamentals.sbc_revenue_ratio
Raw value 16.66% · OPTIONAL
Operating cash flow changed -184.8% from the comparable as-filed period. The change ranks at the 100th percentile of 4 prior comparable changes.
Shares outstanding changed +95.7% from the comparable as-filed period. The change ranks at the 75th percentile of 8 prior comparable changes.
Total assets changed +35.6% from the comparable as-filed period. The change ranks at the 75th percentile of 4 prior comparable changes.
Operating margin changed +110217 basis points from the comparable as-filed period.
Operating income changed -50.3% from the comparable as-filed period.
Stock-based compensation changed +58.5% from the comparable as-filed period. The change ranks at the 75th percentile of 4 prior comparable changes.
Method note “Materiality” here is an analytical magnitude band, not a legal conclusion. Full filing-text semantic changes remain unpublished while excerpt rights and review thresholds are unresolved.
Latest supported period in this snapshot: 2026-06-30. Duration facts use direct quarterly or annual SEC contexts; GrossPattern does not manufacture missing Q4 values.
0001493152-26-034079